NKG-HM42D-100μg / 询价
NKG-HM42D-500μg / 询价
NKG-HM42D-500μgx2 / 询价
- 客服电话
- 技术支持
Human NKG2D/CD314 Protein
Recombinant Human NKG2D/CD314 Protein is expressed from HEK293 with His tag and Avi tag at the N-Terminus.It contains Phe78-Val216 [Accession | P26718].
The protein has a predicted MW of 19.0 kDa. Due to glycosylation, the protein migrates to 36-38 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human NKG2D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human NKG2D, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-NKG2D Antibody, hFc Tag with the EC50 of 6.6ng/ml determined by ELISA (QC Test).
Immobilized Human NKG2D, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human MICA, hFc Tag with the EC50 of 3.2ng/ml determined by ELISA.
Immobilized Human NKG2D, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human ULBP-6, hFc Tag with the EC50 of 2.2ng/ml determined by ELISA.
Human MICB, hFc Tag captured on CM5 Chip via Protein A can bind Human NKG2D, His Tag with an affinity constant of 95.15 nM as determined in SPR assay (Biacore T200).
NKG2D is a type II transmembrane glycoprotein having an extracellular lectin-like domain. This domain lacks the recognizable calcium-binding sites found in true C-type lectins and binds protein rather than carbohydrate ligands. Human NKG2D is expressed on CD8 alpha beta T cells, gamma δ T cells, NK cells and NKT cells.
CD314; D12S2489E; KLR; NKG2-D; NKG2D
(1)Spear P , Barber A , Rynda-Apple A , et al. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors[J]. Immunology and Cell Biology, 2013, 91(6):435-440.
